The partners of Oncobiomics proposed to study the tumoral microbiome have a source of cancer heterogeneity in colon cancer. Their aim is to integrate the intra-tumoral microbiome heterogeneity in order to promote understanding on tumor plasticity and offers new therapeutic options.
Some past studies from the network led up to this project. First, they found a high load of bacteria in colon cancer tumors when compared to non tumoral mucosa and healthy patient mucosa. Moreover, this load is linked to tumor stage. With vivo mice xenograft models, they identified that pks + bacteria induce have a tumor-promoting activity, inducing bigger tumors than other bacterial stems.
First, the network performs a strong characterization of a cohort of 100 colorectal resections and their 100 no tumor adjacent tissue. Samples include tumors from Grade I to grade IV. Characterization is performed at different levels:
Oncobiomics highlights a new alternative to the usual thinking about cancer heterogeneity. Such characterization of colon cancer microbiome heterogeneity and its integration with clinical and genomic aspect of the tumor will promote a new understanding we tumor plasticity and new ways of therapeutic solutions.
This French program is organized by ITMO Cancer, in collaboration with ITMO BCDE (Cell Biology, Development and Evolution) and ITMO Technologies for Health of the National Alliance for Life Sciences and Health (AVIESAN) with the National Cancer Institute (INCA) and Inserm within the framework of the Cancer Plan. Operational management is entrusted to Inserm.
It was launch in order to develop a critical mass of resources and skills in order to conduct interdisciplinary research projects in the field of functional heterogeneity of cellular tumor relations in their ecosystem: the "HTE Program".